ArticleScientific reports2026
Hybrid immunity following SARS-CoV-2 infection and vaccination is associated with more sustained antibody levels, and lower reinfection risk.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Differential functional immune recall across homologous and heterologous COVID-19 vaccination regimens.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A decline in antibody levels against SARS-CoV-2 over time is expected and may lead to breakthrough infections (BTI; infection occurring after vaccination) and reinfections (infection occurring after recovery from a prior SARS-CoV-2 infection). This 12-month longitudinal study investigated the effects of antibody kinetics following SARS-CoV-2 vaccination and infection on the timing and likelihood of BTI or reinfection. Serum IgM, IgA, IgG, and neutralizing antibodies (NAb) against the ancestral SARS-CoV-2 variant were measured in a prospective cohort of 267 participants in Malaysia from March 2021 to May 2023, stratified by the order and timing of SARS-CoV-2 infection and vaccination relative to study enrollment. IgG levels following SARS-CoV-2 infection in individuals previously vaccinated with CoronaVac were higher up to Day 60 compared with those who received BNT162b2 or ChAdOX1 as their primary vaccination; however, antibody levels across vaccine platforms were not statistically different at six months and beyond post-vaccination. The risk of BTI was similar across vaccine platforms, whereas individuals with a history of SARS-CoV-2 infection prior to vaccination showed the lowest subsequent reinfection risk. Breakthrough infections in vaccinated individuals were associated with more sustained IgA, IgG, and NAb levels compared with vaccinated individuals without infection. Our results demonstrate that exposure sequence, rather than vaccine platform alone, is a key determinant of long-term antibody durability and reinfection risk, providing clinically interpretable evidence to inform vaccination strategies in the endemic phase of SARS-CoV-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.